FDA Issues Bone-Chilling Monkeypox Vaccine Warning

This article originally appeared on Sonia Elijah Investigates and was republished with permission.

Guest post by Sonia Elijah

A second small pox vaccine was approved by the U.S. Food and Drug Administration (FDA) for the prevention of mpox was ACAM2000, on August 29th, under Expanded Access Investigational New Drug (EA-IND) protocol.

ACAM2000 is manufactured by the controversial, Emergent BioSolutions. It was originally approved to prevent small pox in 2007.

The side effects of ACAM2000 make a horrifying read.

Not only is death listed as a “serious complication” but alarmingly the FDA’s own medication guide states: “ACAM2000 contains live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those for the vaccinee.”

Meaning that even people who come into close contact with someone who has been vaccinated could possibly die. The packaging insert even states this: “Death has also been reported in unvaccinated contacts accidentally infected by individuals who have been vaccinated.”

According to the CDC:

ACAM2000 is a second-generation vaccine that contains a live vaccinia virus that replicates efficiently in humans. It is manufactured by Emergent Bio Solutions and is indicated for the prevention of smallpox. It has been made available for use against mpox in the clade II outbreak under an Expanded Access Investigational New Drug (EA-IND) protocol, which requires informed consent along with completing additional forms. ……Although the United States has a large supply of ACAM2000, this vaccine has more side effects and contraindications than JYNNEOS.

Notably, on the vaccine information sheet for the other small pox-turned-mpox vaccine, JYNNEOS, it reads: “CDC recommends consideration of the vaccine for people who administer ACAM2000®, or who care for patients infected with orthopoxviruses.”

In June of this year, Emergent BioSolutions “received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). . These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.”

One of the awards included a contract modification valued at $99.9 million to supply ACAM2000^® this year.

What is interesting is that the FDA’s approval of ACAM2000 for the prevention of mpox came on the heels of Emergent BioSolutions pledge to donate 50,000 doses of its vaccine to “Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to address the current mpox outbreak.”

It is also noteworthy that this deadly vaccine was being stockpiled- with the CDC’s comment “the United States has a large supply,” nodding to that fact. The mpox outbreak provided the perfect opportunity to off-load the surplus stock.

It is deeply disturbing that the FDA would approve a vaccine so life-alteringly harmful to not just those being given it- but for those who would come into close contact with the vaccinee. However, unlike the gene-based Covid shots that were branded as “vaccines,” at least the side effects are clearly stated on the medication guide for there to be some kind of informed consent.

This begs the question: how could the deadly ACAM2000 have gotten approval in the first place? Perhaps ,“Dark Winter/ Crimson Contagion” Robert Kadlec and his connections might provide an answer.

Before being appointed by Trump as Assistant Secretary for Preparedness and Response in 2017, Kadlec was previously a consultant for none other than- Emergent BioSolutions. The very same U.S. biotechnology company that purchased ACAM2000 from Sanofi Pasteur in 2017. Kadlec was part-owner of a consulting company RPK Consulting providing services to Emergent, apparently until 2015. He chose not to disclose these facts in Senate nomination forms during his confirmation process in 2017.

Right after taking office, in a resounding conflict of interest move, Kadlec aggressively pushed to increase the government’s stockpile of smallpox vaccine through purchase agreements with Emergent BioSolutions. In the end, the HHS awarded a 10-year, $2.8 billion single-source contract to the company to purchase its smallpox vaccines at twice the previous price.

It is noteworthy that in 1998, Colonel Dr Robert Kadlec, who at the time was the Biodefence Programmes Director at the Department of Homeland Security, wrote in a Pentagon strategy paper: “Using biological weapons under the cover of an endemic or natural disease occurrence provides an attacker the potential for plausible denial. Biological warfare’s potential to create significant economic loss and subsequent political instability, coupled with plausible denial, exceeds the possibilities of any other human weapon.”

Click here to read the rest of the article.

Copyright 2024 Sonia Elijah Investigates